The United States Patent and Trademark Office (USPTO) has granted patent US12582148B2 to FLAASK, LLC, covering novel compositions and methods for treating individuals diagnosed with Autism Spectrum Disorder (ASD). The patent, effective March 24, 2026, details specific formulations that include tellimagrandin II, glycyrrhizin, monolaurin, selenium, honokiol, a probiotic, and one or more biological amphiphilic molecules, intended to support immune and/or digestive health and suppress viral agents.

This patent grant is primarily an intellectual property matter and does not impose direct regulatory obligations on pharmaceutical companies or healthcare providers. However, it signifies a new proprietary development in autism treatment. Companies operating in the pharmaceutical or biotechnology sectors, particularly those involved in developing treatments for neurological or developmental disorders, should be aware of this granted patent as it may affect their research, development, and commercialization strategies in this therapeutic area. No immediate compliance actions are required for entities not directly involved with this specific patent's claims.